King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation addressing its lead product candidate, PH-762, will be given in the American Academy of Dermatology's Late-Breaking Research Session S034 on March 28, 2026 in Denver, Colorado. The presentation, entit ...

Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend this virtual event King of Prussia, Pennsylvania--(Newsfile Corp. - March 16, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today t ...

Summary of Phio Pharmaceuticals Conference Call Company Overview - **Company**: Phio Pharmaceuticals (NasdaqCM:PHIO) - **Industry**: Clinical-stage immuno-oncology focused on treating skin cancers - **Technology**: INTASYL, a proprietary short interfering gene silencing technology aimed at enhancing T-cell effectiveness against tumors [2][3] Market Opportunity - **Target Disease**: Cutaneous squamous cell carcinoma (CSCC) - **Market Size**: Estimated addressable market value of approximately $20 billion, with 1.8 million annual diagnoses [3][24] - **Mortality Rate**: CSCC has an annual death toll approximately twice that of melanoma [3] Technology and Development - **INTASYL Mechanism**: Targets and silences the PD-1 gene, allowing T-cells to attack tumors more effectively [6][10] - **Clinical Trials**: Recently completed Phase 1b trial for PH-762, showing an 85% pathological response rate in the final cohort [15][16] - **Safety Profile**: No immune-related or treatment-related toxicities reported across five dose-escalating cohorts, despite a 20-fold increase in dose concentration [16][25] Competitive Landscape - **Current Treatments**: Existing monoclonal antibodies like Keytruda and Libtayo have total clearance rates of approximately 17% and 11% respectively for advanced skin cancers [26] - **Unique Selling Proposition**: PH-762 offers a direct injection method, potentially reducing systemic side effects and improving patient convenience [16][18] Future Plans - **Next Steps**: Planning to design the next clinical study and seek FDA guidance in Q2 2026, with hopes to commence the next trial in Q1 2027 [18][28] - **Additional Compound**: PH-894, targeting the BRD4 gene, is also in development and expected to enter IND stage following FDA feedback [19][22] Financials - **Cash Runway**: Sufficient funds to support operations into the first half of 2027 [22] - **Shares Outstanding**: 11.6 million common shares, with additional warrants exercisable at $2.05 [22] Leadership and Infrastructure - **Team Composition**: Ultra-lean structure with only eight employees and four subject matter experts, all with extensive experience in drug development [4][23] - **Intellectual Property**: 54 patents issued covering various aspects of the technology, ensuring a strong competitive position [8][24] Conclusion - Phio Pharmaceuticals is positioned to address a significant unmet need in the treatment of cutaneous squamous cell carcinoma with its innovative INTASYL technology, demonstrating promising clinical results and a favorable safety profile, while also planning for future growth and development in the oncology space [24][35]

Core Insights - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][7] - The company will present at the Life Sciences Investor Forum on March 12, 2026, where CEO Robert Bitterman will discuss the INTASYL siRNA platform and recent clinical advancements [1][2] Company Highlights - Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma [5][7] - In a Phase 1b trial, 22 patients completed treatment across five dose-escalation cohorts, reporting a pathological response rate of approximately 65% in cSCC, with an 85% response rate in the highest-dose cohort [5] - The company plans to engage with the FDA regarding the next stage of clinical development in Q2 2026 and has sufficient cash reserves to sustain operations into the first half of 2027 [6] Event Details - The Life Sciences Investor Forum will be held on March 12, 2026, at 11:00 AM ET, allowing real-time Q&A with management [3] - Investors are encouraged to pre-register and check the online system to facilitate participation [4]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36304 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) (State or other jurisdictio ...

Recent Corporate Updates Exhibit 99.1 Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance Sheet with $23.7 Million in Net Proceeds, Extending Cash Runway into the First Half of 2027 KING OF PRUSSIA, PA, March 5, 2026 (NEWSFILE) —Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-s ...

Core Insights - Phio Pharmaceuticals has completed the treatment phase for its lead clinical candidate PH-762, showing favorable safety, tolerability, and pathology data [1][2] - The company has strengthened its balance sheet with $23.7 million in net proceeds from financings and warrant exercises, extending its cash runway into the first half of 2027 [1][5] Clinical Development - PH-762 is being evaluated in a Phase 1b dose-escalating clinical trial for patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, with a total of 22 patients enrolled [2] - The trial aims to assess the safety and tolerability of PH-762 and determine the appropriate dose for further studies, with an FDA submission planned for Q2 2026 [2] Corporate Updates - In July 2025, Phio entered into a drug substance development services agreement with a US manufacturer for the cGMP manufacture of PH-762, supporting future clinical development [3] - A development services agreement was also established in December 2025 for a non-clinical toxicology study required by the FDA before pivotal human trials [4] Financial Performance - As of December 31, 2025, Phio reported cash and cash equivalents of approximately $21.0 million, a significant increase from $5.4 million in 2024 [8] - Research and development expenses rose by 27% to $4.6 million, driven by advancements in the PH-762 program and increased employee compensation [9] - General and administrative expenses increased by 23% to $4.6 million, attributed to higher professional services and stock-based compensation [10] - The net loss for 2025 was approximately $8.7 million, or ($1.45) per share, compared to a net loss of $7.2 million, or ($9.08) per share in 2024 [11][16] Patent Portfolio - Phio's patent portfolio consists of 54 issued patents, with 49 covering the INTASYL platform, including 27 related to immuno-oncology compounds [6] - There are 20 pending patent applications that could enhance the company's therapeutic offerings, with potential expiration dates ranging from 2029 to 2044 [6] Scientific Engagement - In 2025, Phio presented new data on PH-762 at several prominent conferences, including AACR and SITC, and was invited to present at the AAD [7]

Core Viewpoint - Phio Pharmaceuticals Corp. is experiencing a decline in stock price despite no significant news, potentially due to profit-taking after a substantial increase in the previous trading session [1]. Group 1: Clinical Trial Results - The Phase 1b clinical trial for PH-762 demonstrated an 85% pathological response rate at the highest dose concentration, involving 22 patients with cutaneous carcinomas [2][3]. - The Safety Monitoring Committee reported no serious adverse events, indicating a promising outlook for PH-762 as a treatment for skin cancers [3]. Group 2: Future Plans - The company plans to submit for FDA guidance on clinical study design for PH-762 in Q2 2026 and aims to begin manufacturing cGMP material in the second half of 2026 [4]. Group 3: Stock Performance and Technical Indicators - The stock is currently trading 18.4% above its 20-day simple moving average (SMA) but 18.3% below its 100-day SMA, indicating mixed signals [5]. - Over the past 12 months, shares have decreased by approximately 29.51% and are closer to their 52-week lows [5]. - The RSI is at 66.61, indicating neutral territory, while the MACD shows bullish momentum, suggesting mixed momentum for the stock [6]. Group 4: Analyst Consensus - The stock carries a Buy Rating with an average price target of $10.67, with recent analyst actions maintaining a Buy rating and a target of $14.00 [7].

Core Insights - Phio Pharmaceuticals Corp. announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762, leading to a significant increase in share price [1] - The company has a market cap of $9 million and experienced a trading volume of 5.82 million, significantly higher than the average of 412.49 thousand [1] Safety Data Update - The Safety Monitoring Committee reported no serious adverse events or dose-limiting toxicities across all five dose escalation cohorts [2] - The highest dose concentration achieved an pathological response rate of 85%, with complete tumor clearance in four out of six responders [2] Treatment Details - A total of 22 patients with cutaneous carcinomas completed treatment, receiving 4 intratumoral injections of PH-762 [3] - The drug was evaluated in five dose-escalating cohorts, with a 20-fold increase in drug concentration from the first to the fifth cohort [3] Next Steps - An FDA submission for guidance on next steps in clinical study design for PH-762 is targeted for the second quarter of 2026 [4] - The company is on track to have material available for non-human primate studies by March 2026, which is necessary for commencing human pivotal trials [5] Technical Analysis - Phio Pharmaceuticals is currently trading 12.5% below its 20-day simple moving average (SMA) and 17.3% below its 50-day SMA, indicating a bearish trend [6] - Over the past 12 months, shares have decreased by approximately 49.44%, positioning the stock closer to its 52-week lows [6] Price Action - Phio Pharma shares were up 51.11% at $1.36 at the time of publication [8] - Key resistance level is at $1.00, while key support is at 81 cents [8]

Core Insights - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][5] - The company will participate in the DealFlow Discovery Conference on January 28-29, 2026, where CEO Robert Bitterman will present and the management team will hold one-on-one investor meetings [2][3][4] Company Overview - Phio Pharmaceuticals is advancing its INTASYL® gene silencing technology, which aims to enhance the immune system's ability to target and kill cancer cells [5] - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers and is currently in a Phase 1b trial evaluating its efficacy against cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [5] Event Details - The DealFlow Discovery Conference will take place at the Borgata Hotel in Atlantic City, NJ, on January 28-29, 2026 [9] - Investors can register for the conference at no cost to meet with the Phio Pharmaceuticals management team [4]